OLD Category: Oncology

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell of origin-specific clinical impact

• Ennishi D. et al.,

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

• Gao J. et al.,

ALK Expression Is a Novel Marker for the WNT-activated Type of Pediatric Medulloblastoma and an Indicator of Good Prognosis for Patients

• Lastowska M. et al.,

Medulloblastoma with tri-vergent melanocytic, myogenic and cartiligious elements

• Chua F.H.Z. et al.,

Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma

• Qamra A. et al.,

CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic

• Marshall A.D. et al.,

CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer

• Au K.K. et al.,

Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer

• Lindquist KE, et al.

The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia

• Guinn D. et al.,

New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies

• Scott D.W. et al.,

Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression

• Stricker T.P. et al.,

The Identification of Three Cancer Stem Cell Subpopulations within Moderately Differentiated Lip Squamous Cell Carcinoma

• Ram R. et al.,